Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · see citing works

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Gianni, L., Pieńkowski, T., Im, Y., Roman, L., Tseng, L., Liu, M.-C., Lluch, A. M., Starosławska, E., de la Haba-Rodríguez, J., Im, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,387 · see citing works

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,164 · see citing works

Generation of a functional mammary gland from a single stem cell

Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M.-L., Wu, L., Lindeman, G. J., & Visvader, J. E. (2006) · Nature · doi:10.1038/nature04372 · Cited by 2,005 · see citing works

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627 · see citing works

Molecular Definition of Breast Tumor Heterogeneity

Shipitsin, M. V., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,358 · see citing works

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Baselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., de Azambuja, E., Aura, C. M., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317 · see citing works

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

Herschkowitz, J. I., Simin, K. J., Weigman, V., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,287 · see citing works

Hedgehog Signaling and Bmi-1 Regulate Self-renewal of Normal and Malignant Human Mammary Stem Cells

Liu, S., Dontu, G., Mantle, I. D., Patel, S. H., Ahn, N.-S., Jackson, K. W., Suri, P., & Wicha, M. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0054 · Cited by 1,241 · see citing works

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006 · see citing works

The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

Ross, J. S., & Fletcher, J. A. (1998) · Stem Cells · doi:10.1002/stem.160413 · Cited by 990 · see citing works

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · see citing works

Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

Hennessy, B. T., Gonzalez-Angulo, A. M., Stemke‐Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J., Fridlyand, J., Şahin, A. A., Agarwal, R., Joy, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3441 · Cited by 874 · see citing works

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance

Zhou, J., Wulfkuhle, J. D., Zhang, H., Gu, P., Yang, Y., Deng, J., Margolick, J. B., Liotta, L. A., Petricoin, E., & Zhang, Y. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702596104 · Cited by 699 · see citing works

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Bendell, J. C., Rodon, J. A., Burris, H. A., de Jonge, M. J. A., Verweij, J., Birle, D. C., Demanse, D., Buck, S. S. D., Ru, Q. C., Peters, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 687 · see citing works

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzmán, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 533 · see citing works

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Maira, S.-M., Pecchi, S., Huang, A., Burger, M. T., Knapp, M. S., Sterker, D., Schnell, C., Guthy, D. A., Nagel, T., Wiesmann, M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 533 · see citing works

Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling

Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S. G., & Wicha, M. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000121 · Cited by 523 · see citing works

Activation of an IL-6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2 Overexpressing Breast Cancers by Expanding the Cancer Stem Cell Population

Korkaya, H., Kim, G., Davis, A., Malik, F., Henry, N., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecules and Cells · doi:10.1016/j.molcel.2012.06.014 · Cited by 518 · see citing works

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

Garrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D. M., Sanchez, V. M., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W. J., McKinely, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016140108 · Cited by 469 · see citing works

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

Chakrabarty, A., Sanchez, V. M., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347 · see citing works

Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α ( <i>PIK3CA</i> )

Burke, J. E., Perisic, O., Masson, G. R., Vadas, O., & Williams, R. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205508109 · Cited by 300 · see citing works

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285 · see citing works

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms

Liu, P., Cheng, H.-L. M., Santiago, S., Raeder, M. B., Zhang, F., Isabella, A. J., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2402 · Cited by 258 · see citing works

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

Chandarlapaty, S., Sakr, R. A., Giri, D. D., Patil, S. N., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N. X., Hudis, C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1785 · Cited by 229 · see citing works

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse

Harrell, J. C., Prat, A., Parker, J. S., Fan, C., He, X., Carey, L., Anders, C. K., Ewend, M. G., & Perou, C. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1619-7 · Cited by 228 · see citing works

Akt/PKB-Mediated Phosphorylation of Twist1 Promotes Tumor Metastasis via Mediating Cross-Talk between PI3K/Akt and TGF-β Signaling Axes

Xue, G., Restuccia, D. F., Lan, Q., Hynx, D., Dirnhofer, S., Heß, D., Rüegg, C., & Hemmings, B. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0270 · Cited by 214 · see citing works

Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells

Herschkowitz, J. I., Zhao, W., Zhang, M., Usary, J., Murrow, G., Edwards, D., Knezevic, J., Greene, S. B., Darr, D. B., Troester, M. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018862108 · Cited by 209 · see citing works

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

Garrett, J. T., & Arteaga, C. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15045 · Cited by 179 · see citing works

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)

Oliveras‐Ferraros, C., Corominas-Faja, B., Cufí, S., Vázquez‐Martín, A., Martı́n-Castillo, B., Iglesias, J. M., López‐Bonet, E., Martín, Á. G., & Menéndez, J. A. (2012) · Cell Cycle · doi:10.4161/cc.22225 · Cited by 146 · see citing works

Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells

Reim, F., Dombrowski, Y., Ritter, C., Buttmann, M., Häusler, S. F., Ossadnik, M., Krockenberger, M., Beier, D., Beier, C. P., Dietl, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0834 · Cited by 129 · see citing works

HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice

Finkle, D., Quan, Z. R., Asghari, V., Kloss, J., Ghaboosi, N., Mai, E., Wong, W. L., Hollingshead, P., Schwall, R., Koeppen, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0448 · Cited by 125 · see citing works

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3

Chakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S., Engelman, J. A., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.257 · Cited by 102 · see citing works

Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations

Yuan, W., Stawiski, E. W., Janakiraman, V., Chan, E., Durinck, S., Edgar, K. A., Kljavin, N. M., Rivers, C. S., Gnad, F., Roose‐Girma, M., et al. (2012) · Oncogene · doi:10.1038/onc.2012.53 · Cited by 77 · see citing works

Physiological Levels of Pik3caH1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors

Tikoo, A., Roh, V., Montgomery, K. G., Ivetac, I., Waring, P., Pelzer, R., Hare, L., Shackleton, M. J., Humbert, P. O., & Phillips, W. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036924 · Cited by 64 · see citing works

Highly sensitive profiling of CD44+/CD24− breast cancer stem cells by combining global mRNA amplification and next generation sequencing: Evidence for a hyperactive PI3K pathway

Hardt, O., Wild, S., Oerlecke, I., Hofmann, K., Luo, S., Wiencek, Y., Kantelhardt, E., Vess, C., Smith, G. P., Schroth, G. P., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.06.010 · Cited by 64 · see citing works

Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes

Wallin, J. J., Guan, J., Edgar, K. A., Zhou, W., Francis, R., Torres, A. C., Haverty, P. M., Eastham‐Anderson, J., Arena, S., Bardelli, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036402 · Cited by 48 · see citing works

Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.

Dirix, L., Romieu, G., Provencher, L., Grimes, D., Viana, L. D. S., Paterson, A. H. G., Mauriac, L., Kirsch, A., Pernas, S., & Miles, D. W. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-4116 · Cited by 48 · see citing works

Mouse models of PIK 3 CA mutations: one mutation initiates heterogeneous mammary tumors

Koren, S., & Bentires‐Alj, M. (2013) · FEBS Journal · doi:10.1111/febs.12175 · Cited by 39 · see citing works

The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes

Pereira, B., Chin, S., Rueda, O. M., Vollan, H. K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L. R., Russell, R., Sammut, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,712 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

The PI3K/AKT Pathway as a Target for Cancer Treatment

Mayer, I. A., & Arteaga, C. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 826 · see citing works

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604 · see citing works

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438 · see citing works

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Zotano, Á. G., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 419 · see citing works

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors

Millis, S. Z., Ikeda, S., Reddy, S. B., Gatalica, Z., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0891 · Cited by 318 · see citing works

Cancer-Associated PIK3CA Mutations in Overgrowth Disorders

Madsen, R. R., Vanhaesebroeck, B., & Semple, R. K. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.003 · Cited by 276 · see citing works

Breast Cancer Molecular Stratification

Russnes, H. G., Lingjærde, O. C., Børresen‐Dale, A., & Caldas, C. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.022 · Cited by 276 · see citing works

PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

Loibl, S., von Minckwitz, G., Schneeweiß, A., Paepke, S., Lehmann, A., Rezai, M., Zahm, D. M., Sinn, H., Khandan, F., Eidtmann, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7876 · Cited by 258 · see citing works

Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives

Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 245 · see citing works

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

Yang, S. X., Polley, E. C., & Lipkowitz, S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.004 · Cited by 239 · see citing works

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

Dey, N., De, P. K., & Leyland-Jones, B. R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 232 · see citing works

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

Li, H., Prever, L., Hirsch, E., & Gulluni, F. (2021) · Cancers · doi:10.3390/cancers13143517 · Cited by 229 · see citing works

Efficacy of PI3K inhibitors in advanced breast cancer

Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221 · see citing works

Integrating Network Pharmacology and Pharmacological Evaluation for Deciphering the Action Mechanism of Herbal Formula Zuojin Pill in Suppressing Hepatocellular Carcinoma

Guo, W., Huang, J., Wang, N., Tan, H., Cheung, F., Chen, F., & Feng, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01185 · Cited by 211 · see citing works

Synergy in activating class I PI3Ks

Burke, J. E., & Williams, R. L. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.003 · Cited by 216 · see citing works

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

Kadara, H. N., Choi, M., Zhang, J., Parra, E. R., Rodriguez‐Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C.-W. B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw436 · Cited by 200 · see citing works

Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients

Chen, L., Liu, Y., Yao, L., Kuang, X.-Y., Zuo, W., Li, S., Qiao, F., Liu, Y., Cao, Z.-G., Zhou, S.-L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03867-9 · Cited by 170 · see citing works

At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy

Vasan, N., & Cantley, L. C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00633-1 · Cited by 167 · see citing works

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer

Janiszewska, M., Liu, L., Almendro, V., Kuang, Y., Paweletz, C. P., Sakr, R. A., Weigelt, B., Hanker, A. B., Chandarlapaty, S., King, T. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3391 · Cited by 163 · see citing works

Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer

Siravegna, G., Lazzari, L., Crisafulli, G., Bianchi, A. S., Mussolin, B., Cassingena, A., Martino, C., Lanman, R. B., Nagy, R. J., Fairclough, S. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.004 · Cited by 158 · see citing works

Co-Occurring Gain-of-Function Mutations in HER2 and HER3 Modulate HER2/HER3 Activation, Breast Cancer Progression, and HER2 Inhibitor Sensitivity

Hanker, A. B., Brown, B. P., Meiler, J., Marín, A., Jayanthan, H. S., Ye, D., Lin, C.-C. A., Akamatsu, H., Lee, K., Chatterjee, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2021.06.001 · Cited by 104 · see citing works

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers

Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 102 · see citing works

Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness

Parida, P. K., Marquez-Palencia, M., Nair, V. R., Kaushik, A., Kim, K., Sudderth, J., Quesada-Diaz, E., Cajigas, Á., Vemireddy, V., Ericsson, P. I. G., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.001 · Cited by 99 · see citing works

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer

Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sanchez, V. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2808 · Cited by 102 · see citing works

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Hanker, A. B., Garrett, J. T., Estrada, M. V., Moore, P. D., Ericsson, P. I. G., Koch, J. P., Langley, E. J., Singh, S., Kim, P. S., Frampton, G. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2287 · Cited by 96 · see citing works

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer

Dillon, L. M., Bean, J. R., Yang, W., Shee, K., Symonds, L. K., Balko, J. M., McDonald, W. H., Liu, S., Gonzalez-Angulo, A. M., Mills, G. B., et al. (2014) · Oncogene · doi:10.1038/onc.2014.328 · Cited by 87 · see citing works

Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer

Ma, F., Guan, Y., Yi, Z., Chang, L., Li, Q., Chen, S., Zhu, W., Guan, X., Li, C., Qian, H., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32536 · Cited by 88 · see citing works

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells

Rexer, B. N., Chanthaphaychith, S., Dahlman, K. B., & Arteaga, C. L. (2014) · Breast Cancer Research · doi:10.1186/bcr3601 · Cited by 80 · see citing works

Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells

Truffi, M., Colombo, M., Sorrentino, L., Pandolfi, L., Mazzucchelli, S., Pappalardo, F., Pacini, C., Allevi, R., Bonizzi, A., Corsi, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24968-x · Cited by 79 · see citing works

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells

Canfield, K., Li, J., Wilkins, O. M., Morrison, M. M., Ung, M. H., Wells, W. A., Williams, C. R., Liby, K. T., Vullhorst, D., Buonanno, A., et al. (2015) · Cell Cycle · doi:10.4161/15384101.2014.994966 · Cited by 76 · see citing works

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers

Sun, B., Mason, S., Wilson, R. C., Hazard, E. S., Wang, Y., Fang, R., Wang, Q., Yeh, E. S., Yang, M., Roberts, T. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0953-9 · Cited by 75 · see citing works

Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas

Ebbesen, S. H., Scaltriti, M., Bialucha, C. U., Morse, N., Kastenhuber, E. R., Wen, H. Y., Dow, L. E., Baselga, J. M., & Lowe, S. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523693113 · Cited by 72 · see citing works

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer

Yi, Z., Rong, G., Guan, Y., Li, J., Chang, L., Li, H., Liu, B., Wang, W., Guan, X., Ouyang, Q., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00201-9 · Cited by 70 · see citing works

PI3K in stemness regulation: from development to cancer

Madsen, R. R. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190778 · Cited by 68 · see citing works

Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis

Bertacchini, J., Guida, M., Accordi, B., Mediani, L., Martelli, A. M., Barozzi, P., Petricoin, E. F., Liotta, L. A., Milani, G., Giordan, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.123 · Cited by 67 · see citing works

Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner

Madsen, R. R., Knox, R. G., Pearce, W. P., López, S., Mahler-Araujo, B. M., McGranahan, N., Vanhaesebroeck, B., & Semple, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821093116 · Cited by 67 · see citing works

PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Rasti, A. R., Guimarães-Young, A., Datko, F. M., Borges, V. F., Aisner, D. L., & Shagisultanova, E. I. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00370 · Cited by 64 · see citing works

Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma

Fang, W., Zhao, S., Liang, Y., Yang, Y., Yang, L., Dong, X., Zhang, L., Shoufeng, W., Yang, Y., Yang, Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0547 · Cited by 62 · see citing works

Cancer stem cells and HER2 positive breast cancer: The story so far

Shah, D., & Osipo, C. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.02.002 · Cited by 62 · see citing works

PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer

Markou, A. N., Farkona, S., Schiza, C., Efstathiou, T., Kounelis, S., Malamos, N., Georgoulias, V., & Lianidou, E. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0149 · Cited by 61 · see citing works

Implications of stemness-related signaling pathways in breast cancer response to therapy.

Angeloni, V., Tiberio, P., Appierto, V., & Daidone, M. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.08.004 · Cited by 60 · see citing works

Far Beyond the Usual Biomarkers in Breast Cancer: A Review

Pultz, B. D. A., da Luz, F. A. C., de Faria, P. R., Oliveira, A. P. L., de Araújo, R. A., & Silva, M. J. B. (2014) · Journal of Cancer · doi:10.7150/jca.8925 · Cited by 59 · see citing works

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives

Fuso, P., Muratore, M., D’Angelo, T., Paris, I., Carbognin, L., Tiberi, G., Pavese, F., Duranti, S., Orlandi, A., Tortora, G., et al. (2022) · Cancers · doi:10.3390/cancers14092161 · Cited by 54 · see citing works

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer

Arienti, C., Zanoni, M., Pignatta, S., Río, A. D., Carloni, S., Tebaldi, M., Tedaldi, G., & Tesei, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7575 · Cited by 54 · see citing works

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance

Zhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 54 · see citing works

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*

Young, C. D., Zimmerman, L. J., Hoshino, D., Formisano, L., Hanker, A. B., Gatza, M. L., Morrison, M. M., Moore, P. D., Whitwell, C. A., Dave, B., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.049783 · Cited by 53 · see citing works

PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer

Zhang, H., Zhang, L., He, Y., Jiang, D., Sun, J. L., Luo, Q., Liang, H., Wang, T., Li, F., Tang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217112 · Cited by 51 · see citing works

Identifying and targeting tumor-initiating cells in the treatment of breast cancer

Wei, W., & Lewis, M. T. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0447 · Cited by 51 · see citing works

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review

Zhong, H., Zhou, Z., Wang, H., Wang, R., Shen, K., Huang, R., & Wang, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413376 · Cited by 50 · see citing works

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data

Jagosky, M. H., & Tan, A. R. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s176514 · Cited by 54 · see citing works

HER2 in Solid Tumors: More than 10 Years Under the Microscope; where are we now?

Martin, V., Cappuzzo, F., Mazzucchelli, L., & Frattini, M. (2014) · Future Oncology · doi:10.2217/fon.14.19 · Cited by 48 · see citing works

PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling

Cheng, H.-L. M., Liu, P., Ohlson, C. E., Xu, E., Symonds, L., Isabella, A., Muller, W. J., Lin, N., Krop, I. E., Roberts, T. M., et al. (2015) · Oncogene · doi:10.1038/onc.2015.377 · Cited by 46 · see citing works

PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers

Wang, Q., Liu, P., Spangle, J. M., Von, T., Roberts, T. M., Lin, N., Krop, I. E., Winer, E. P., & Zhao, J. J. (2015) · Oncogene · doi:10.1038/onc.2015.406 · Cited by 46 · see citing works

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

Schwarz, L. J., Hutchinson, K. E., Rexer, B. N., Estrada, M. V., Ericsson, P. I. G., Sanders, M. E., Dugger, T. C., Formisano, L., Zotano, Á. G., Red-Brewer, M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx065 · Cited by 47 · see citing works

Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3–NANOG Axis

Oh, S. J., Cho, H., Kim, S., Noh, K. H., Song, K., Lee, H.-J., Woo, S. R., Kim, S., Choi, C. H., Chung, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2325 · Cited by 45 · see citing works

A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer

Lampignano, R., Yang, L., Neumann, M., Franken, A., Fehm, T. N., Niederacher, D., & Neubauer, H. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091885 · Cited by 45 · see citing works

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study

Yang, G., Yang, Y., Liu, R., Li, W., Xu, H., Hao, X., Li, J., Xing, P., Zhang, S., Ai, X., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221082339 · Cited by 44 · see citing works

Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease

Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44 · see citing works

PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma

Eze, N., Lee, J., Yang, D., Zhu, F., Neumeister, V. M., Sandoval-Schaefer, T., Mehra, R., Ridge, J. A., Forastiere, A. A., Chung, C. H., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.02.026 · Cited by 40 · see citing works

The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings

Shor, R. E., Dai, J., Lee, S., Pisarsky, L., Matei, I. R., Lucotti, S., Lyden, D. C., Bissell, M. J., & Ghajar, C. M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13031 · Cited by 39 · see citing works

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes

Hart, V., Gautrey, H., Kirby, J. A., & Tyson-Capper, A. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27789 · Cited by 39 · see citing works

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

Armaghani, A. J., & Han, H. S. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s219436 · Cited by 37 · see citing works

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3558 · Cited by 38 · see citing works

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas

Martı́n-Castillo, B., López‐Bonet, E., Cuyàs, E., Viñas, G., Pernas, S., Dorca, J., & Menéndez, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6094 · Cited by 35 · see citing works

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

Belli, V., Matrone, N., Napolitano, S., Migliardi, G., Cottino, F., Bertotti, A., Trusolino, L., Martinelli, E., Morgillo, F., Ciardiello, D., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1230-z · Cited by 36 · see citing works

Precision Combination Therapies Based on Recurrent Oncogenic Coalterations

Li, X., Kong, E., Yan, G., Dereli, Z., Bozorgui, B., Imanirad, P., Elnaggar, J. H., Luna, A., Menter, D. G., Pilie, P. G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0832 · Cited by 35 · see citing works

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

Gu, Y., Gao, H., Zhang, H., John, A. J., Zhu, X., Shivaram, S., Yu, J., Weinshilboum, R. M., & Wang, L. (2022) · Oncogene · doi:10.1038/s41388-022-02415-6 · Cited by 35 · see citing works

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA -Mutated HER2-Positive Metastatic Breast Cancer

Jhaveri, K. L., Drago, J. Z., Shah, P. D., Wang, R., Pareja, F. G., Ratzon, F., Iasonos, A. E., Patil, S. N., Rosen, N. X., Fornier, M. N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0047 · Cited by 34 · see citing works

Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms

Shi, H., Zhang, W., Zhi, Q., & Jiang, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5467-2 · Cited by 33 · see citing works

A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers

Hamalian, S., Güth, R., Runa, F., Sanchez, F., Vickers, E., Agajanian, M. J., Molnar, J., Nguyen, T. M., Gamez, J., Humphries, J. D., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01906-2 · Cited by 32 · see citing works

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy

Creedon, H., Gómez-Cuadrado, L., Tarnauskaitė, Ž., Balla, J., Canel, M., MacLeod, K. G., Serrels, B., Fraser, C., Unciti‐Broceta, A., Tracey, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7317 · Cited by 33 · see citing works

Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.

Dey, N., Sun, Y., Carlson, J. H., Wu, H., Lin, X., Leyland-Jones, B. R., & De, P. K. (2016) · PubMed Central · Cited by 31 · see citing works

Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype

Madsen, R. R., Erickson, E. C., Rueda, O. M., Robin, X., Caldas, C., Toker, A., Semple, R. K., & Vanhaesebroeck, B. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009876 · Cited by 31 · see citing works

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer

Sueta, A., Yamamoto, Y., Yamamoto‐Ibusuki, M., Hayashi, M., Takeshita, T., Yamamoto, S., & Iwase, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116054 · Cited by 30 · see citing works

Targeting Receptor Tyrosine Kinases in Cancer

Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 26 · see citing works

Clinical applications of mouse models for breast cancer engaging HER2/neu

Fry, E. A., Taneja, P., & Inoue, K. (2016) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000210 · Cited by 27 · see citing works

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors

Abramson, V. G., Supko, J. G., Ballinger, T. J., Cleary, J. M., Hilton, J. F., Tolaney, S. M., Chau, N. G., Cho, D. C., Pearlberg, J., Lager, J. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1764 · Cited by 29 · see citing works

Targeting the Breast Cancer Kinome

Miller, S. M., Goulet, D. R., & Johnson, G. L. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25427 · Cited by 27 · see citing works

Synergistic interactions with PI3K inhibition that induce apoptosis

Zwang, Y., Jonas, O. H., Chen, C., Rinne, M. L., Doench, J. G., Piccioni, F., Tan, L., Huang, H., Wang, J., Ham, Y. J., et al. (2017) · eLife · doi:10.7554/elife.24523 · Cited by 28 · see citing works

Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models

Lu, Y., Houson, H. A., Gallegos, C., Mascioni, A., Jia, F., Aivazian, A., Song, P. N., Lynch, S. E., Napier, T. S., Mansur, A., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01844-3 · Cited by 27 · see citing works

Novel treatment strategies for patients with HER2‑positive breast cancer who do not benefit from current targeted therapy drugs (Review)

Jiang, N., Lin, J., Wang, J., Zhang, B., Li, A., Chen, Z., Guo, S., Li, B., Duan, Y., Yan, R., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6459 · Cited by 27 · see citing works

PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta‐analysis

Fan, H., Li, C., Xiang, Q., Xu, L., Zhang, Z., Liu, Q., Zhang, T., Zhou, Y. F., Zhao, X., & Cui, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12618 · Cited by 26 · see citing works

Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations

Chen, J. W., Murugesan, K., Newberg, J. Y., Sokol, E. S., Savage, H. M., Stout, T. J., Maund, S. L., & Hutchinson, K. E. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00341 · Cited by 26 · see citing works

Pharmacogenomic and molecular docking studies on the cytotoxicity of the natural steroid wortmannin against multidrug-resistant tumor cells

Kuete, V., Saeed, M. E. M., Kadioglu, O., Börtzler, J., Khalid, H., Greten, H. J., & Efferth, T. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.11.011 · Cited by 26 · see citing works

Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial

Huang, L., Chen, S., Yang, W., Xu, B., Huang, T., Yang, H., Zheng, H. Y., Wang, Y., Song, E., Zhang, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4337 · Cited by 23 · see citing works

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition

McNeill, R. S., Stroobant, E. E., Smithberger, E., Canoutas, D. A., Butler, M. K., Shelton, A., Patel, S. D., Limas, J. C., Skinner, K., Bash, R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200014 · Cited by 25 · see citing works

Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations

Mitchell, C. B., & Phillips, W. A. (2019) · Biomolecules · doi:10.3390/biom9040158 · Cited by 24 · see citing works

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

Hurvitz, S. A., Sadeghi, S., & Olevsky, O. M. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s47524 · Cited by 24 · see citing works

Current status of the prognostic molecular biomarkers in breast cancer: A systematic review

Kutomi, G., Mizuguchi, T., Satomi, F., Maeda, H., Shima, H., Kimura, Y., & Hirata, K. (2017) · Oncology Letters · doi:10.3892/ol.2017.5609 · Cited by 23 · see citing works

PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum

Goel, S., & Krop, I. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw246 · Cited by 22 · see citing works

Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer

Hu, X., Li, D., Fu, Y.-J., Zheng, J., Feng, Z., Cai, J., & Wang, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.917439 · Cited by 21 · see citing works

Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene

Yong, C. S. M., Sharkey, J., Duscio, B., Venville, B., Wei, W., Jones, R. F., Slaney, C. Y., Arnau, G. M., Papenfuss, A. T., Schröder, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136817 · Cited by 21 · see citing works

Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers

Young, C. D., Arteaga, C. L., & Cook, R. S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0656-2 · Cited by 22 · see citing works

The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness

Ha, J. R., Siegel, P. M., & Ursini‐Siegel, J. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25561 · Cited by 20 · see citing works

PtdIns(3,4,5)P 3 -dependent Rac exchanger 1 (P-Rex1) promotes mammary tumor initiation and metastasis

Srijakotre, N., Liu, H.-J., Nobis, M., Man, J., Yip, H. Y. K., Papa, A., Abud, H. E., Anderson, K. I., Welch, H. C. E., Tiganis, T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006445117 · Cited by 20 · see citing works

Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data

Chen, H., Hu, X., Wang, D., Wang, Y., Yu, Y., & Yao, H. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101738 · Cited by 20 · see citing works

Precision medicine and personalized breast cancer: combination pertuzumab therapy

Dizon, D. S., Reynolds, K., Sarangi, S., & Bardia, A. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s37100 · Cited by 20 · see citing works

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

Garay, J. P., Smith, R. L., Devlin, K. L., Hollern, D. P., Liby, T. A., Liu, M., Boddapati, S. P., Watson, S. S., Esch, A. M., Zheng, T., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01457-0 · Cited by 19 · see citing works

Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies

Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sanchez, V. M., Sutton, C. R., Cheng, H.-L. M., Perou, C. M., Zhao, J. J., et al. (2013) · Molecular Cancer Research · doi:10.1158/1557-3125.advbc-a007

Abstract 4875: Human HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo

Hanker, A. B., Kuba, M. G., Sanchez, V. M., Sutton, C. R., Pfefferle, A. D., Balko, J. M., Perou, C. M., Cook, R. S., & Arteaga, C. L. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-4875 · Cited by 50 · see citing works

Abstract 1822: HER2/PIK3CAH1047R transgenic tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab, and PI3K inhibitors via multiple mechanisms

Hanker, A. B., Young, C. D., Stricker, T. P., Cook, R. S., & Arteaga, C. L. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1822

Abstract PD5-8: HER2/PIK3CAH1047R transgenic mammary tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab and PI3K inhibitors via multiple mechanisms

Hanker, A. B., Bulen, B., Brewer, M. R., Young, C. D., Farrar, K. M., Cook, R. S., Stricker, T. P., & Arteaga, C. L. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-pd5-8

PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling

Cheng, H.-L. M., Liu, P., Ohlson, C. E., Xu, E., Symonds, L., Isabella, A., Muller, W. J., Lin, N., Krop, I. E., Roberts, T. M., et al. (2015) · Oncogene · doi:10.1038/onc.2015.377 · Cited by 46 · see citing works